Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
LQT Therapeutics Announces Closing of US$19M Series A Financing
Details : LQTT is advancing a series of in- licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing